This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Badawi, A. F. Articles by Badr, M. Z. Search for Related Content PubMed PubMed Citation Articles by Badawi, A. F. Articles by Badr, M. Z.

Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor

¹ Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, and ² School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri

We examined the effect of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, and N-(9-fluorenyl-methyloxycarbonyl)-L-leucine (F-L-Leu), a peroxisome proliferator-activated receptor (PPAR) agonist, separately and combined, on the development of methylnitrosourea (MNU)-induced rat mammary gland carcinogenesis. Celecoxib and F-L-Leu significantly reduced tumor incidence and multiplicity (P < 0.05). Combining both agents exerted higher (synergistic) cancer inhibition than separate treatments (P < 0.05). The effects of the test drugs on COX-2 and PPAR expression and on the synthesis of prostaglandin E₂ (PGE₂) and 15-deoxy-^12,14-PGJ₂ (15d-PGJ₂) were examined in rat mammary normal (MNU-untreated), uninvolved, and tumor (MNU-treated) tissues. Celecoxib and F-L-Leu, separately, inhibited COX-2 and up-regulated PPAR expression. These effects were paralleled by inhibition of PGE₂ synthesis and up-regulation of 15d-PGJ₂. Combined treatment resulted in higher alterations in COX-2 and PPAR transcripts and PG synthesis compared with separate administrations. The effect of the test agents on Bcl₂, BAX, and protein kinase C expression levels were examined in the rat mammary gland and the pro-(BAX:Bcl₂) and anti-[PKC*(Bcl₂/BAX)] apoptotic ratios were evaluated. Each drug increased the proapoptotic ratio by 2- to 7-fold and reduced the antiapoptotic ratio by 2- to >8-fold in all tissues. Combined treatment, however, resulted in >9- to 14-fold up-regulation in the proapoptotic processes and 15- to >30-fold down-regulation in the antiapoptotic ones. Analyses were also carried out on the drug-induced modulation of cell cycle regulators and proliferation markers (cyclin-dependent kinase 1 and proliferating cell nuclear antigen). F-L-Leu and celecoxib each reduced the cyclin-dependent kinase 1 and proliferating cell nuclear antigen expression in the tumor. Higher down-regulation was attained in all tissues by combined treatment where cyclin-dependent kinase 1 and proliferating cell nuclear antigen almost retained the expression levels observed in the normal glands. In conclusion, simultaneous targeting of COX-2 and PPAR may inhibit mammary cancer development more effectively than targeting each molecule alone. COX-2 inhibitors and PPAR agonists coordinately mediate their anticancer effect via both COX-dependent (inhibition of COX-2, activation of PPAR, and modulation PG synthesis) and COX-independent (induction of proapoptotic factors and inhibition of cell proliferation) pathways.

This article has been cited by other articles:

				F. Ondrey Peroxisome Proliferator-Activated Receptor {gamma} Pathway Targeting in Carcinogenesis: Implications for Chemoprevention Clin. Cancer Res., January 1, 2009; 15(1): 2 - 8. [Abstract] [Full Text] [PDF]

				E. Horia and B. A. Watkins Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells Carcinogenesis, April 1, 2007; 28(4): 809 - 815. [Abstract] [Full Text] [PDF]

				S. Stadlmann, U. Gueth, E. Wight, L. A Kunz-Schughart, A. Hartmann, and G. Singer Expression of peroxisome proliferator activated receptor {gamma} and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma J. Clin. Pathol., March 1, 2007; 60(3): 307 - 310. [Abstract] [Full Text] [PDF]

				M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]

				B. Zhang, H. Cao, and G. N. Rao Fibroblast Growth Factor-2 Is a Downstream Mediator of Phosphatidylinositol 3-Kinase-Akt Signaling in 14,15-Epoxyeicosatrienoic Acid-induced Angiogenesis J. Biol. Chem., January 13, 2006; 281(2): 905 - 914. [Abstract] [Full Text] [PDF]

				Retraction: Article on Inhibition of Carcinogenesis in Rat Mammary Glands Cancer Res., September 1, 2005; 65(17): 8057 - 8057. [Full Text] [PDF]

				B. Zhang, H. Cao, and G. N. Rao 15(S)-Hydroxyeicosatetraenoic Acid Induces Angiogenesis via Activation of PI3K-Akt-mTOR-S6K1 Signaling Cancer Res., August 15, 2005; 65(16): 7283 - 7291. [Abstract] [Full Text] [PDF]

				B. Rigas and K. Kashfi Cancer Prevention: A New Era beyond Cyclooxygenase-2 J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 1 - 8. [Abstract] [Full Text] [PDF]

				J. Lu, K. Imamura, S. Nomura, K.-i. Mafune, A. Nakajima, T. Kadowaki, N. Kubota, Y. Terauchi, G. Ishii, A. Ochiai, et al. Chemopreventive Effect of Peroxisome Proliferator-Activated Receptor {gamma} on Gastric Carcinogenesis in Mice Cancer Res., June 1, 2005; 65(11): 4769 - 4774. [Abstract] [Full Text] [PDF]

				C. J. Nicol, M. Yoon, J. M. Ward, M. Yamashita, K. Fukamachi, J. M. Peters, and F. J. Gonzalez PPAR{gamma} influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis Carcinogenesis, September 1, 2004; 25(9): 1747 - 1755. [Abstract] [Full Text] [PDF]

				A. F. Badawi, Y. Liu, M. B. Eldeen, W. Morrow, Z. R. Razak, M. Maradeo, and M. Z. Badr Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate Carcinogenesis, September 1, 2004; 25(9): 1681 - 1688. [Abstract] [Full Text] [PDF]